Skip to main content
SpringerLink
Log in

Is radiofrequency ablation effective in patients with early-stage hepatocellular carcinoma and cirrhosis?

  • Practice Point
  • Published:

From Nature Clinical Practice Oncology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Dupuy DE and Goldberg SN (2001) Image-guided radiofrequency tumor ablation: challenges and opportunities—Part II. J Vasc Interv Radiol 12: 1135–1148

    Article  CAS  Google Scholar 

  2. Livraghi T et al. (1999) Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 210: 655–661

    Article  CAS  Google Scholar 

  3. Lau WY et al. (2003) Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg 237: 171–179

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Livraghi T et al. (2000) Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 214: 761–768

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Dr Jean-Francois Geschwind, Associate Professor and Director of Vascular and Interventional Radiology, Johns Hopkins Hospital, Baltimore, MD, USA.

Author information

Authors and Affiliations

  1. Director of Abdominal Intervention and Tumor Ablation and Director of the Minimally Invasive Tumor Therapy Laboratory at Beth Israel Deaconess Medical Center, and an Associate Professor of Radiology at Harvard University, Boston, MA, USA

    S Nahum Goldberg

Authors
  1. S Nahum Goldberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S Nahum Goldberg.

Ethics declarations

Competing interests

Dr Goldberg receives sponsored research support and is on the advisory board of Valleylab, Boulder, CO, a manufacturer of radiofrequency ablation devices. He also receives research support from the NCI.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goldberg, S. Is radiofrequency ablation effective in patients with early-stage hepatocellular carcinoma and cirrhosis?. Nat Rev Clin Oncol 2, 438–439 (2005). https://doi.org/10.1038/ncponc0285

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0285

  • Springer Nature Limited

Search

Navigation